Epilepsy is one of the most common chronic neurological disorders; it affects 1% of the world’s population, yet about 1 in 3 patients fail to achieve seizure control with current drugs. We will improve the properties of small molecules (drugs) that specifically target the GTPase activity of the enzyme dynamin, to reduce seizure effect in the brain by a novel mechanism. We will optimize and pre-clinically test these future chemical entities as potential anti-epileptic drugs.
Mitochondria are both the powerhouses and the poison cupboard of our cells. They have evolved from bacteria and still possess the ability to grow and divide. Unregulated mitochondrial division is seen in dying cells and in cells from patients with neurodegenerative diseases. We have identified new molecules involved in mitochondrial division and are investigating how they function in normal and unhealthy cells.
Mechanism Of Action Of Dynamin Ring Stabilizer Compounds Controlling The Actin Cytoskeleton
Funder
National Health and Medical Research Council
Funding Amount
$659,360.00
Summary
We will test our hypothesis that ring stabilizer (RS) compounds we invented may become future proteinuric kidney disease therapeutics. The global epidemic of kidney disease eludes present treatments. Dysfunction of podocyte cells accounts for 90% of end-stage kidney diseases. Our pilot data shows that our ring stabilizer compounds restore podocyte function in vitro and kidney function in animal models. We aim to understand their mechanism of action.